Asymptomatic diabetic patients with different degrees of macrovascular complications can present different hemostatic changes. At this study, plasminogen activator inhibitor-1 (PAI-1) and D-dimer were evaluated in 12 women without diabetes and 64 type 2 diabetic women. All patients were classified into 3 different categories according to the carotid intima-media thickness (IMT) assessed by Doppler: 25 with <1 mm (normal), 15 with >1 mm and without plaque (intermediate), and 24 with stenosis lower than 50% of the vessel lumen (plaque). The results showed increased plasma D-dimer in type 2 diabetic women with carotid plaque when compared to the other groups. High levels of PAI-1 were observed in all the 3 groups of diabetic women when compared to women without diabetes. Our results suggest that high levels of PAI-1 in type 2 diabetic women are only associated with diabetes and are not associated with macrovascular progression; however, it seems that D-dimer plasma levels are associated with carotid plaque.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1076029609334626 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the utility of the sFlt-1/PlGF ratio in pregnancy complicated by pre-eclampsia - single-center study. Preliminary analysis.
Ginekol Pol
January 2025
Department of Obstetrics and Perinatology, Jagiellonian University Medical College, Cracow, Poland, Poland.
Objectives: To evaluate relationship between sFlt-1/PlGF ratio, clinical characteristics and outcomes of pre-eclampsia.
Material And Methods: Retrospective analysis of 29 pregnant women with pre-eclampsia who had measured sFlt-1/PlGF ratio was conducted using electronic medical records from Obstetrics and Perinatology ward of University Hospital in Cracow.
Results: Women median age: 33.
The role of Anti-Müllerian hormone in women health.
Ginekol Pol
January 2025
Department of Clinical Dietetics, Faculty of Health Sciences, Medical University of Warsaw, Poland, Poland.
Anti-Müllerian hormone (AMH), also known as Müller duct inhibitory factor and primarily known for its role in sexual differentiation. In female fetuses, AMH production by granulosa cells begins around the 36th week of gestation and continues in women until menopause. It is becoming more significant in the endocrine and gynecological diagnosis of adult women.
View Article and Find Full Text PDFUpdate on Menopause Hormone Therapy; Current Indications and Unanswered Questions.
Clin Endocrinol (Oxf)
January 2025
Women's Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, 3004, VIC, Australia.
Objective: To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT).
Design: The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data.
Patients: The review focuses on MHT-related outcomes in women with natural-timed menopause captured within observational studies, RCTs, and pooled data from pivotal meta-analyses and reviews.
Demographic and clinical characteristics of older people with multimorbidity accessing primary healthcare in Malawi: A cross-sectional study.
J Multimorb Comorb
January 2025
Department of Health Systems and Policy, Kamuzu University of Health Sciences, Blantyre, Malawi.
Background: Multimorbidity is a growing global concern, affecting patient outcomes and healthcare costs. In low- and middle-income countries, data on multimorbidity in primary care beyond prevalence is limited. Our study explored the demographic and clinical characteristics of multimorbidity among older people attending primary health care in Malawi.
View Article and Find Full Text PDFImpact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a): A Meta-Analysis and Meta-Regression of Randomized Controlled Trials.
JACC Adv
February 2025
Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk.
Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a) levels across multiple trials.
Methods: Studies were retrieved comparing the effect of PCSK9i vs placebo on Lp(a) levels.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!